Dipharma To Acquire CRO Kalexsyn
Dipharma, a Baranzate, Italy-headquartered active pharmaceutical ingredients manufacturer, has agreed to acquire Kalexsyn, a Kalamazoo, Michigan-headquartered contract research organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry.
Founded in 2003 by Robert Gadwood and David Zimmermann, Kalexsyn provides chemistry services that primarily support the drug-discovery activities of their customers. These services include custom synthesis, stable label synthesis, process impurity synthesis, and process route-improvement work. Kalexsyn employs synthetic organic chemists with experience in drug-discovery and process development at large pharmaceutical companies.
Kalexsyn will continue its current business, operating from its headquarters in Michigan, and following the completion of the transaction, David Zimmermann and Robert Gadwood will continue to lead the company under the new ownership.
Dipharma is planning to invest in Kalexsyn to add cGMP and highly potent active pharmaceutical ingredient capabilities in support of Phase I and early Phase II development to the existing building site. Design activities have begun with an anticipated ground-breaking later in 2018 with the facility expected to be fully operational by the fourth quarter of 2019. Kalexsyn currently provides non-GMP process development. Addition of these capabilities will allow the new company to provide an array of integrated services from discovery research through commercialization.
The transaction is expected to close within a month.